Earth Science Tech, Inc. (OTCQB: ETST) Breaking News - September 13, 2018

The CBD Bonanza on the Horizon

New York NY - September 13, 2018 - CannabisNewsWire Editorial Coverage - Leveraging ever-expanding scientific evidence of the therapeutic efficacy of CBD (cannabidiol), specialty biotechnology companies are creating novel new formulations of the chemical compound to capitalize on the titanic growth expected in the cannabis-derived pharmaceutical and nutraceutical markets.

• Global medical marijuana market expected to exceed $55 billion by 2025

• Global nutraceuticals market projected to surpass $319 billion by 2023

• CBD pharmaceutical and nutraceutical companies poised to reap huge rewards

• Diverse CBD product lines provide competitive advantages

 Another Milestone

Eyes on the Prize

 The company has four distinct, wholly owned subsidiaries:

• Cannabis Therapeutics, Inc. (CTI) is developing an array of cannabinoid-based pharmaceuticals and nutraceuticals.

• Kannabidioid, Inc. manufactures and distributes vapes/e-liquids and gummy edibles to vape and smoke shops.

• Earth Science Pharmaceutical, Inc. (ESP) manufactures low-cost medical devices and vaccines for protection against sexually-transmitted infections.

• Earth Science Foundation, Inc., a nonprofit organization formed to accept grants and donations to conduct further studies and help donate CBD products to those in need.
   

Not a One-trick Pony

Others Vying for Position 

The Takeaway

For more information about Earth Science Tech, please visit Earth Science Tech, Inc. (OTCQB: ETST).

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

Receive Text Alerts from CannabisNewsWire: Text "Cannabis" to 21000

For more information please visit https://www.CannabisNewsWire.com and or https://CannabisNewsWire.News

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

DISCLAIMER: CannabisNewsWire (CNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with CNW or any company mentioned herein. The commentary, views and opinions expressed in this release by CNW are solely those of CNW and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable CNW and FNM for any investment decisions by their readers or subscribers. CNW and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, CNW, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.

CNW & FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and CNW and FNM undertake no obligation to update such statements.

CannabisNewsWire (CNW) & NetworkNewsWire (NNW) are proud to be affiliated partners of the Investor Brand Network (IBN)

About IBN

Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Please feel free to visit the Investor Brand Network (IBN) http://www.InvestorBrandNetwork.com

Corporate Communications Contact:

CannabisNewsWire (CNW)Denver, Coloradowww.CannabisNewsWire.com 303.498.7722 Office Editor@CannabisNewsWire.net

 Media Contact:  FN Media Group, LLC NNW@FinancialNewsMedia.com   +1-(954)345-0611

Source:  CannabisNewsWire

NetworkNewsBreaks – Earth Science Tech, Inc. (ETST) Announces Completion of Audit Process, Submits Form 10 to Become Fully Reporting

https://www.networknewswire.com/networknewsbreaks/networknewsbreaks-earth-science-tech-inc-etst-announces-completion-of-audit-process-submits-form-10-to-become-fully-reporting/

New York NY - May 15, 2018 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company focused on the cannabidiol (CBD), nutraceutical and pharmaceutical fields as well as medical devices and research and development, this morning announced that its audit process has been finalized, and the company has submitted Form 10 to become fully reporting. “I am very proud of the hard work done by our team to complete the audits,” Dr. Michael Aube, CEO and chief science officer of ETST, stated in the news release. “These efforts will be rewarded by the positive reception of our current and future investors. Transparency is a key tool that we needed to accelerate the growth of our business. Since all of our amazing projects are ongoing with our partners, investor confidence will grow, and we will be able to complete our first big round of financing. We are in touch with institutional and private investors that were waiting for ETST to become a fully reporting company before investing the necessary amount to commercialize our projects. We can now resume our discussions with them.”

To view the full press release, visit http://nnw.fm/6KhUm

About Earth Science Tech, Inc.

Earth Science Tech, Inc. (“ETST”) offers the highest purity and quality, high-grade full spectrum cannabinoid oil on the market. Thanks to its positive result studies on breast cancer and immune cells through the University of Central Oklahoma, studies through DV Biologics proving to lower cortisol and as a neuroprotectant, positive result case studies through key health organizations. ETST formulates, markets, and distributes the CBD oil used for its studies to the public, offering the most effective quality of CBD in the market. For more information, visit the company’s website at www.EarthScienceTech.com

Diversity Spells Success in the Cannabis Market

Special NetworkNewsWire Coverage:

https://www.networknewswire.com/networknewsaudio/cannabinoids-lead-marijuana-biotech-boom/

https://www.networknewswire.com/earth-science-tech-inc-s-etst-european-industrial-hemp-mr-checkout-key-players-2018/

https://www.networknewswire.com/networknewsbreaks/networknewsbreaks-earth-science-tech-inc-etst-advances-prosperous-cannabis-industry/

New York, NY – February 2018 – NetworkNewsWire.com News Coverage:  As the legalization of medical marijuana spreads, the appetite for investment in the cannabis biotech sector keeps growing. This is the largest sector of the legal cannabis market, already a multi-billion-dollar market. Researchers continue to uncover new ways that cannabinoids, chemical compounds found in cannabis, can be used as medicine. Earth Science Tech (OTC: ETST) offers full-spectrum, high-grade hemp cannabidiol (CBD) oil, and is researching cutting-edge CBD products through its subsidiary Cannabis Therapeutics, Inc. (CTI). The creator of the first cannabis-based prescription medicine, GW Pharma (NASDAQ: GWPH) is working on new drugs to tackle epilepsy, while Medical Marijuana, Inc. (OTC: MJNA) provides a range of CBD oils with medical and nutritional benefits to customers across North and South America. CV Science, Inc. (OTC: CVSI) utilizes separate drug development and consumer product divisions to create and market a diverse range of CBD products to a variety of markets, and Cannabis Science, Inc. (OTC: CBIS) is developing formulation-based drugs based on cannabinoid science.

A Thriving New Sector

The legal cannabis sector is booming. According to the Brightfield Group, it is already worth over $7 billion and expected to grow to $31 billion by 2021. Within that market, CBD products are a significant sector, expected to hit $1 billion in the next few years. Even the more conservative U.S. states are overcoming their objections and opening up to CBD production and sales, as legislators seek to resolve legal ambiguities in favor of patients.

While the emergence of a recreational cannabis market in regions such as Canada and California is exciting news for the cannabis industry, the industry’s financial security rests on medical products. The loosening of laws makes research easier, as does the growing experience of medical cannabis companies. CBD is a particularly rich source of therapeutics with the potential to be utilized against a wide range of ailments. Researchers are exploring its potential to tackle such enduring problems as epilepsy, anxiety, depression and breast cancer.

Innovating in Cannabidiol

Biotechnology company Earth Science Tech (OTC: ETST) has diverse interests within the cannabis market. Its subsidiaries cover diagnostics and vaccines, recreational cannabis and CBD products. In that last area, it’s leading the way in researching and marketing a wide variety of CBD-based treatments through innovative partnerships and collaborative research.

Earth Science Tech’s CBD work is carried out through its subsidiary Cannabis Therapeutics, Inc. (CTI). The company’s CBD oil is 100 percent natural and organic, catering to the environmental concerns common among cannabis users. It is made using a CO2 liquid extraction process that results in a full-spectrum, high-grade hemp CBD oil that has the highest purity and quality on the market.

To keep it in the lead of the CBD market, Earth Science Tech has created partnerships with other research bodies to produce cutting-edge treatments. It is working with the University of Central Oklahoma and DV Biologics Laboratory on research and development projects to enhance the healthcare benefits of its CBD oil. This has positioned the company to take a leadership role in the development of cannabinoid-based pharmaceutical and nutraceutical products. The company holds a provisional application patent for a CBD product for treating breast and ovarian cancers, taking CBD treatments in bold new directions.

Reaching New Market Sectors

Cannabis Therapeutics currently has two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products in development. These are being made to treat a range of ailments including anxiety, depression and fatty liver disease.

One major focus is integrating the CBD molecule with existing generic drug molecules to create more efficient medications that have fewer side effects than the more common approaches. The company is therefore engaged not only in making cannabinoids useful and available to a wider range of patients, but in creating a better experience for existing patients.

Other research into medical cannabinoids by Earth Science Tech could counter conservative fears about the impact of medical cannabis on the illegal drug market. In November 2017, the company began human trials on a new CBD formula designed to decrease cravings and the negative effects of withdrawal in opioid addicts. Based on industrial hemp CBD mixed with a natural ingredient that increases dopamine levels, it could be used to counter the opioid epidemic plaguing many countries. By turning medical CBD into a weapon in the fight against addiction, it will reposition cannabis in the public discourse on drug use. This has the potential to counter resistance to the expansion of the medical cannabis market.

Raising the Brand Profile

Earth Science Tech has a wide variety of products, giving it good reach within the CBD market. Its CBD treatments are available as vitamins, minerals, herbs, botanicals, personal care products, homeopathic treatments and foods. Other products come in forms including capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Available at retail stores across the United States and online, they have a combination of physical shelf presence and online visibility to raise their profile with consumers.

The company is currently rebranding its CBD products (http://nnw.fm/s6pC1), using market research to drive improved sales. The chief marketing officer commented, “We did a lot of market research to see what the best angle to truly stand out in the growing CBD industry is through our accounts, representative feedback, and external brand analysis. I feel that marketing, ‘High Grade Full Spectrum Cannabinoids’ will help ETST truly stand out. Soon, the market will be able to see that Earth Science Tech (OTC: ETST) is a true full spectrum CBD brand, especially with the cannabinoid complex listing under the supplement facts.”

As a result of this research, previous marketing of the company’s products as, “High Grade Hemp CBD Oil” is being replaced with “High Grade Full Spectrum Cannabinoids.” Branding will also include the addition of “Cannabinoid Complex”. The supplement facts will show the breakdown of the full spectrum of CBD oils being used, including CBD, CBG and CBDA.

Box packaging has been designed to incorporate these changes and a modern, edgy look while maintaining the clean design associated with medicinal products.

Better Distribution

Taking these revamped products into American stores (http://nnw.fm/pd51A) is the first major distributor for Earth Science Tech’s products — Mr. Checkout.

Mr. Checkout, as featured on ABC’s Shark Tank, is a national group of independent distributors, full-line grocery distributors and convenience stores. It represents products in over 60 major U.S. retail outlets with approximately 55,000 stores. Mr. Checkout’s accounts include Walgreens, CVS, Walmart, Wholefoods Market and Target. This distribution deal provides a direct route for Earth Science Tech’s products onto the shelves of powerful retail stores with a large consumer base.

Earth Science Tech has 10 active representatives opening and managing accounts across the United States. These representatives have been very successful with health food stores and clinics. The distribution agreement with Mr. Checkout will take the company’s products beyond this market, into major retailers and stores, substantially expanding the company’s reach.

Gabriel Aviles, Earth Science Tech’s chief sales officer and director, said about the deal, “I feel that we have finally put together a solid productive team of representatives that we needed to continue expanding our presence in health shops and clinics. Now, with Mr. Checkout, we will be able to take our presence and sales to the next level, entering larger retailers and many stores. 2018 looks to be starting off very strong with our new product revamp, marketing and education strategy, and sales channel.”

Growing Consumer Choice

The growth of the medical cannabis sector means that Earth Science Tech’s products sit among a wide range of brands on the ever-growing shelves of CBD oils.

British cannabis company GW Pharma (NASDAQ: GWPH) has developed Sativex, the first prescription medicine derived from the marijuana plant. This has been approved for Multiple Sclerosis spasticity and neuropathic pain in 29 countries. The company is currently seeking FDA approval for Epidiolex, a CBD-based treatment for epilepsy, after the drug was found to be effective in clinical trials.

Medical Marijuana (OTC: MJNA), one of the pioneers of the cannabis sector in North and South America, offers its flagship product Real Scientific Hemp Oil (RSHO) in three varieties. RSHO was the first legal CBD oil in both Brazil and Mexico, and the company was the first publicly traded cannabis business in the United States. A global leader in the medical marijuana industry, this forward-looking company is also exploring the nutritional potential of hemp.

CV Science (OTCQB: CVSI) is divided into two segments: a drug development division focused on creating and commercializing novel CBD-based therapeutics, and a consumer product division that manufactures, markets and sells plant-based CBD products. It is tapping into a wide range of market sectors through products such as its Purified Liquids products for vaping. Its PlusCBD Oil is the top-selling brand of hemp-derived CBD oil for consumers in the natural products industry.

Recognizing the long history of cannabinoids for health purposes and supporting peer-reviewed scientific journals, Cannabis Science (OTC: CBIS) is focused on the discovery and development of novel cannabinoid-based therapies as treatment options for unmet medical needs. Its immediate focus is on the treatment of cancer. 

Cannabinoids are an increasingly important part of the growing cannabis sector. Companies that can combine strong branding, customer outreach and innovative products are likely to see great growth as the market expands by billions each year. And as research finds new therapeutic uses for these chemicals, they are set to improve the lives of thousands of patients.

For more information on Earth Science Tech, visit Earth Science Tech (OTC: ETST)

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, please visit https://www.NetworkNewsWire.com.

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.  The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

 NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).

About IBN

Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Please feel free to visit the Investor Brand Network (IBN) www.InvestorBrandNetwork.com

Corporate Communications Contact:

NetworkNewsWire (NNW)

New York, New York

www.NetworkNewsWire.com 

212.418.1217 Office

Editor@NetworkNewsWire.com   

Media Contact:

FN Media Group, LLC

NNW@FinancialNewsMedia.com  

+1-(954)345-0611

Diversity Spells Success in the Cannabis Market

Special NetworkNewsWire Coverage:
https://www.networknewswire.com/clients/earth-science-tech-inc-etst/?symbol=etst 

https://www.networknewswire.com/?s=etst 

New York, NY – February, 2018 – NetworkNewsWire.com News Coverage:  For the growing population of investors within the cannabis market, marijuana-related portfolios are frequently designed to be diverse — an advisable investment strategy for any trading portfolio. From the cultivation side of the cannabis sector to biotech/medical/pharmaceutical, ancillary services, cannabis oils, edibles and beyond, the different avenues for marijuana investment are abundant. For companies like Earth Science Tech, Inc. (OTC: ETST), the existence of diversity within its own operations offers a similar advantage, enabling the company to touch on and benefit from the success of various subsectors within the cannabis market. Though uniquely structured, ETST is paced alongside other cannabis industry players like Insys Therapeutics, Inc. (NASDAQ: INSY), Namaste Technologies, Inc. (CSE: N), (OTC: NXTTF), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) and Emerald Health Therapeutics, Inc. (TSX-V: EMH) (OTC: EMHTF).

A Diverse Arena

The forward-march of cannabis legalization throughout North America has led to record-breaking growth within this market, and business opportunities have gone far beyond the bud to include assorted products like gourmet marijuana edibles, cannabis-derived oils, cannabis-based pharmaceuticals, health and beauty products, vape pens and smoking accessories, agricultural innovations, payment solutions, and more.

As decriminalization efforts continue worldwide, the cannabis market only grows stronger. A recent Bloomberg report cites Brightfield Group’s prediction that legal cannabis sales will reach $31 billion on a global level by 2021 (http://nnw.fm/Xo0Ts). Like the individual strands in a rope, the diverse subsectors within the cannabis market are twining together to form an increasingly strong whole.

Strength in Variety

For companies like Earth Science Tech, Inc. (OTC: ETST), operating diversified subsidiaries is proving to be favorable path of growth within the cannabis market. The innovative biotech currently has three wholly owned subsidiaries under its umbrella, building an effective tripod of strength for the company. Though these subsidiaries are diverse in nature, their synergy lies in the application of science to the pursuit of optimal health.

Launched in February 2017, the Cannabis Therapeutics, Inc. (“CTI”) subsidiary is purposed to develop proprietary cannabinoid-based nutraceuticals and pharmaceutical products. At the core of this mission are Earth Science Tech’s existing cannabis cannabidiol (CBD) patent, IP and future technologies to be developed.

Focused on exploring and harnessing the medicinal power of CBD, CTI’s research and development efforts are geared toward the development of CBD-based drugs and nutraceuticals; and the integration of the CBD molecule with existing generic drug molecules to make drugs more efficient with fewer and less severe side effects.

The subsidiary’s pipeline includes two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products for a variety of ailments, such as anxiety, depression, triple negative breast cancer and fatty liver disease.

CTI positions ETST in the rapidly evolving cannabinoid-based pharmaceuticals market, which Statista projects could reach $50 billion by the year 2029. Meanwhile, a report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021.

Discovering New Revenue Streams

ETST again extended its reach in June 2017 when it entered into a joint venture to launch its wholly owned KannBidoid, Inc. (“KBD”) subsidiary (http://nnw.fm/c6VBH).

Positioned to take advantage of the recreational vape/smoke shop space, each of KBD’s products is formulated with CBD and kanna — a small groundcover plant natively found in southern Africa — sold and distributed in the form of edibles and vapes/e-liquids products.

Rooted Research & Development

Though not centered on cannabis, ETST’s Earth Science Pharmaceutical, Inc. subsidiary represents the core of the company’s R&D capabilities.

Earth Science Pharmaceutical is focused on the development of low-cost, noninvasive diagnostic tools, medical devices, testing processes, and vaccines for sexually transmitted infections (STI) and/or diseases. Its first medical device, MSN-2, is a home detection STI kit being prepared for molecular diagnostics trials.

The subsidiary is managed by an executive team with years of scientific, medical and business experience in health, research and manufacturing. The expertise of this team — headed by ETST CEO and SCO Dr. Michael Aubé and COO Nickolas Tabraue — provides each of ETST’s subsidiaries a multi-dimensional approach to their respective markets.

Strategic Expansion via Acquisition & Partnerships

In 2017 Earth Science Tech also increased operational diversity with the acquisition of Montreal-based Canna Inno Laboratories, which provides Earth Science Tech, Inc. (OTC: ETST) access to government grants for up to half of its R&D expenditures.
ETST also has agreements with the Centre de Développement Bioalimentaire du Québec (“CDBQ”), which specializes in helping companies develop the processes needed to take a prototype agro-food or nutraceutical product to industrial-scale production for the marketplace; and with Brazilian company, Bionatus. Inc. to develop a treatment for asthma (http://nnw.fm/PE43r).

Branded Cannabidiol

Leveraging the strategies of its subsidiaries, ETST continues to raise brand visibility, offering full-spectrum, high-purity hemp-derived CBD oil. In collaboration with the University of Central Oklahoma and the DV Biologics Laboratory, the company is conducting R&D projects designed to scientifically support the health care benefits of its completely natural and organic CBD oil.

Earth Science Tech’s products include CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathics, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. They are available at retail stores throughout the United States, as well as online.

The company has also started pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD oil mixed with a known natural ingredient proven to help increase dopamine levels.

2017 Performance Points to 2018 Potential

As discussed in a recent article (http://nnw.fm/pd0Md) and year-end review (http://nnw.fm/38VbO), ETST nearly doubled its revenues in 2017 compared with the previous year, and a price target of more than $4 has been set for its stock.

ETST’s achievements in 2017 add weight to Dr. Aubé’s positive forecast for the company’s future.

“This past year has been amazing. I am elated about the start of the New Year given all that we accomplished in 2017. … We have built the foundation and infrastructure the Company needs to succeed long-term … and I feel that we are now on the way to becoming the next billion-dollar (in-capitalization) company on the OTC Markets.”

Comparable Cannabis Players

Insys Therapeutics (NASDAQ: INSY) is focused on improving patient care by addressing unmet medical needs through cannabinoids and novel drug delivery systems. The company’s approved products include SYNDROS, a cannabinoid medicine used to treat anorexia in adults with AIDS and to address nausea and vomiting caused by chemotherapy, and SUBSYS, which is used to manage breakthrough pain in adult cancer patients who have become tolerant to opioid therapy.

Namaste Technologies (OTCQB: NXTTF) is an online retailer of medical cannabis delivery systems, distributing vaporizers and smoking accessories worldwide through e-commerce websites in 26 countries and five distribution hubs. Through its 2017 acquisition of CannMart Inc., Namaste is pursuing a new revenue vertical in online medical cannabis retail sales in the Canadian market, with an aim of positioning itself as a retail medical cannabis distribution leader in Canada. During 2018, Namaste intends to establish a secure telemedicine portal that will connect doctors with medical marijuana patients, allowing Canadian patients to receive product recommendations via email and to have their prescriptions filled via postal mail. The company further plans to expand its product offerings in 2017 and to launch a Canadian warehouse in the CannMart facility.

Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) is a clinical-stage pharmaceutical company that is focused on developing and commercializing novel therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. Lenabasum is the company’s lead product candidate and is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. It is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus.

Emerald Health Therapeutics (OTCQX: EMHTF) is an emerging global cannabis player and, through its wholly owned subsidiary Emerald Health Botanicals Inc., is a licensed producer of medical marijuana in Canada through the Access to Cannabis for Medical Purposes Regulations (ACMPR). The company currently operates an indoor facility in Victoria, B.C., and is in the process of constructing a 500,000-square-foot greenhouse in Metro Vancouver that has expansion potential to 1 million square feet. Emerald additionally owns 50 percent of Pure Sunfarms Inc. (a partnership with Village Farms International Inc.), which is currently converting just under half of its 1.1 million-square-foot greenhouse in Delta, B.C., from a tomato-growing operation into a cannabis-cultivation facility.

Broadening the Landscape

Diversity is advisable for any investment portfolio, and innovative companies like Earth Science Tech are proving diversity’s effectiveness as a business strategy as well. As the global cannabis market continues to gain strength, the above-mentioned companies are positioned to lead the way into the foreseeable green future.

For additional information about Earth Science Tech, visit Earth Science Tech, Inc. (OTC: ETST)

About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.


Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.

NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertakes no obligation to update such statements.

NetworkNewsWire (NNW) is affiliated with the Investor Brand Network (IBN).

About IBN
Over the past 10+ years we have consistently introduced new network brands, each specifically designed to fulfil the unique needs of our growing client base and services. Today, we continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Please feel free to visit the Investor Brand Network (IBN) www.InvestorBrandNetwork.com

Corporate Communications Contact:
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Media Contact:
FN Media Group, LLC
NNW@FinancialNewsMedia.com
+1-(954)345-0611

News Source: NetworkNewsWire
 

________________________
Recent ETST News:

Earth Science Tech, Inc. President Commits to Donating 50,000 of his Personal Shares to Become the First Contributor to Earth Science Foundation

Doral, FL, Jan. 18, 2018 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of cannabinoid (CBD), nutraceutical and pharmaceutical and is focused on R&D for certain medical devices, announced today that Company President Nickolas S. Tabraue has committed to donating 50,000 of his personal shares to become the first contributor to Earth Science Foundation (the ”Foundation”). The Foundation has been formed to help individuals who are in need of the products the Company manufactures as well as future formulas that are being developed by the Company in order to meet their health needs.

The Foundation which was discussed in a press release earlier this month is the Company’s nonprofit entity, designed to assist patients who need assistance with obtaining products produced by the Company in order to meet their medical needs. The company is currently in the process of qualifying as a 501 (c)(3) organization and becoming structured with key individuals to help those in need, the Company is currently in discussions with medical practitioners, organizations and schools to secure donations for ETST’s popular and effective cannabinoid products.

The Foundation’s goal is to help individuals suffering from cancer, epilepsy, autism, addiction and chronic pain who are not able to afford ETST’s products assisting them in obtaining these products at a reasonable price or at no cost. ETST plans to include participating organizations and those taking part in human trials and to provide them with the benefits and supplies at our cost following the conclusion of these studies. To help fund this effort, Earth Science Foundation will accept donations on its GoFundMe Page

Gabriel Aviles, ETST’s chief sales officer, who will soon be named as the Company’s chief learning officer, will help educate the participating organizations regarding the benefits of cannabinoids and will further provide education on the studies he plans to conduct. The Company is finalizing preparations to launch its anti-opioid cannabinoid formula and is ready to study its cannabinoid formula on autism symptoms, given the significant positive feedback the Company has received from individuals diagnosed with autism.

Mr. Aviles comments, “We are at the forefront of a new frontier in modern medicine. We have seen the tremendous potential our formulas have to improve the health of our patients, and we want to formally research and share our results and our life-changing treatments with as many people as we can, Our ability to do this stems from the education we provide. I will do my best to educate students, teachers, parents and the medical community on the benefits we have discovered in CBD-based treatments.”

Mr. Tabraue, the Company’s president, director and COO, has agreed to donate the shares of compensation he is to receive for Q1 2018, equal to 50,000 shares, to the Foundation. The shares will be used as an asset for the Foundation as it continues to grow and requires additional funds to help meet its obligations.

Mr. Tabraue concludes, “I have received a tremendous amount of positive feedback regarding our CBD-based products from children, adults and elderly patients alike who are suffering from cancer, epilepsy, chronic pain and autism, just to name a few. Nothing feels better than knowing my Company’s products have helped change peoples’ lives in a positive way. I do know there are many patients who are not able to purchase our products and they seek extra help in addition to the discounts we offer. Through the Foundation, I feel we can truly help those in need continue to find improved health.. As mentioned earlier, I am currently in talks with many great medical practitioners, schools and organizations, and I plan on sharing updates as they progress.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil, please visit: www.earthsciencetech.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118

Source: Earth Science Tech, Inc.

NetworkNewsWire Coverage:  Earth Science Tech, Inc. (ETST)

GET IN-DEPTH COVERAGE PROVIDED BY NETWORKNEWSWIRE FOR ETST HERE

Earth Science Tech, Inc. is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.

Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.    GET IN-DEPTH COVERAGE PROVIDED BY NETWORKNEWSWIRE FOR ETST HERE

________________________
Recent ETST News:

Earth Science Tech, Inc. Appoints New Board Member, Mr. Avi Levy, Esq., to Develop Canadian Market

Doral, FL, Jan. 09, 2018 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device R&D, is pleased to announce the appointment of Mr. Avi Levy, Esq. as the company’s legal consultant for Canadian activities.

With Mr. Levy’s expertise as a highly-regarded lawyer, the company plans to expand its business in Canada. Levy has been practicing law for over twenty-two years and has been involved in both criminal and civil law since the beginning of his practice. He started his career at one of the biggest law firms in Canada, where he worked in tax and estate law, dealing mostly with regulatory issues, and as a prosecutor. He went on to advise and act as general counsel to some of the biggest internet companies, in addition to top athletes and celebrities in the United States. Most recently, Mr. Levy established himself as an expert in the medical marijuana industry, representing some of Canada’s largest clinics and counseling them on regulatory and legal issues.

Mr. Levy will help the company apply for licenses to import its CBD-rich hemp oil into Canada, where it will be transformed and exported in bulk as raw hemp oil, or in individual ready-to-consume bottles. CBD-rich hemp oil is growing in popularity around the world, and ETST hopes to soon begin exporting from its Canadian facilities to various different countries. The company will also profit from the new Canadian market that is opening for cannabis edible products.

“We will be well prepared for that new market. We will manufacture and start to distribute our 3 new CBD-based nutraceutical products in USA in 2018 and in 2019, following our application to get a license to work with schedule II controlled substances,” said Mr. Levy, “We will develop new products with a mix of CBD and THC-rich cannabis oil. In Canada there will be a huge amount of production of dried cannabis herb, and we will profit from purchasing and transforming the excess stock these companies create.”

“We are very excited to welcome Mr. Avi Levy, Esq. to our board of directors,” said CEO & CSO, Michel Aubé, “He brings with him decades of experience in advising companies and individuals in rapid-growth environments, has personal connections to top brands and celebrities, and has worked directly with the cannabis industry. We can’t wait to explore the synergies we have with him, and watch our Canadian prospects grow.”

About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118

Source: Earth Science Tech, Inc.

Earth Science Tech, Inc. Announces New Agreement with a Private Laboratory to Develop and Commercialize MSN-2 Medical Device

Doral, FL, Jan. 09, 2018 - Earth Science Tech, Inc. (OTC: ETST) ("ETST" or "the Company"), an innovative biotech company that operates in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device R&D, is pleased to announce the company has signed a deal with Laboratories BNK Canada, Inc. (http://www.labobnk.com/), for clinical studies related to the MSN-2 Medical Device. BNK is a private laboratory, which will conduct the clinical studies required to add more tests to the company’s MSN-2 medical device-related services.

ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea. In the near future, ETST will add testing for trichomoniasis, and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. Both are highly infectious sexually transmitted infections (STI). These additions will help the company create sales opportunities in new markets.

BNK brings a team of professional scientists from the pharmaceutical, clinical research, and even hospital settings. BNK will assist ETST in the design, development, and validation of testing methods that meet all regulatory requirements. In addition, BNK will assist with the determination and development of study-specific tests for ETST clinical projects and bring expertise in clinical research project management to ensure that all trials run smoothly. This expertise will help the company maintain efficiency and reduce R&D costs.

“We are on the cusp of making tremendous progress in our clinical trial efforts,” said Dr. Michel Aubé, CEO and CSO of ETST. He continued, “Our partnership with BNK will allow us to leverage the expertise of R&D veterans of many years, which will help us move more quickly, develop more products, cut costs, and ultimately, treat more patients.”

Chlamydia and other sexually transmitted infections (STIs) often have permanent consequences for patients, and damage society at large. The World Health Organization now recommends that all pregnant women be tested for chlamydia, which has created a very large testing market. This partnership with BNK is expected to help ETST increase its total attainable market in this space, and allow the company to commercialize its new testing services more quickly.

“We are extremely happy to be working with Earth Science Tech on their MSN-2 project,” said Dr Gilles Brisson, President and Scientific Director at BNK . “This project has the potential to completely change the way we look at sampling for STI infections and is certainly a positive development in Women’s Health around the world. This collaboration will be the fundamental driver for the success of this project”.

It is essential that the spread of Sexually Transmitted Infections (STI) be halted. Michel Aubé PhD, Chief Science Officer states, “STI can have severe consequences. It is very important to prevent spreading. For example we can cure the Chlamydia infections but any permanent damage done by the long term infection will not be repaired.” Currently, two women are infected with Chlamydia for each infected man, and women generally have more complications. They may develop pelvic inflammatory disease, which leads to sterility, as well as chronic pain that persists even after the infection is cured. A newborn infected with Chlamydia by the mother may develop pneumonia and/or conjunctivitis that can lead to permanent blindness. For this reason, the World Health Organization recommends that all pregnant women be tested for Chlamydia. For these reasons, the market for Chlamydia testing alone is huge. ETST now has the laboratory partner needed to support the company’s R&D and the commercialization of its MSN-2 medical device, which has been specifically developed to support women’s health and the related molecular diagnostics that women desperately need access to.

About Earth Science Tech, Inc. (ETST): Earth Science Tech has among the highest quality, purity, and full spectrum High Grade Hemp CBD (Cannabidiol) Oil on the market. Made using the superior supercritical CO2 liquid extraction, our CBD Oil is 100% natural and organic. Our research, performed alongside the University of Central Oklahoma and DV Biologics laboratory, demonstrate that we are the top nutritional and dietary supplement brand for High Grade Hemp CBD Oil.

To learn more and to buy CBD Hemp Oil please visit: www.earthsciencetech.com

About Earth Science Pharmaceutical: Earth Science Pharmaceutical, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc (ETST). Earth Science Pharmaceutical is focused on becoming a world leader in the development of low cost, non-invasive diagnostic tools, medical devices, testing processes and vaccines for STIs (Sexually Transmitted Infections and/or Diseases). Earth Science Pharmaceutical CEO, Dr. Michel Aubé, a renowned scientist, is committed to help grow ETST in the medical and pharmaceutical industry.

To learn more please visit: www.Earthsciencepharmaceutical.com

About Cannabis Therapeutics: Cannabis Therapeutics, Inc. is a wholly owned subsidiary of Earth Science Tech, Inc. (ETST). Cannabis Therapeutics, Inc. was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis cannabinoid-based pharmaceuticals, nutraceuticals as well as other products & solutions. Cannabis Therapeutics mission it to help change the healthcare landscape by introducing their proprietary cannabis-cannabinoid based products made for both the pharmaceutical and retail consumer markets worldwide.

To learn more please visit: www.Cannabisthera.com

About KannaBidioiD: KannaBidioid, Inc. is wholly owned subsidiary of Earth Science Tech, Inc. (ETST). KannaBidioid, Inc. is focused in the recreational space to manufacture and distribute vapes/e-liquids and gummy edibles in the recreational space formulated by its unique Kanna and CBD formula. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhance focus, and help with nicotine addiction based on their properties.

To learn more please visit: www.kannabidioidinc.com

SAFE HARBOR ACT: Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Dave Demarest (305) 546-7640
Earth Science Tech, Inc. Nickolas S. Tabraue, P/D/COO (305) 615-2118

Source: Earth Science Tech, Inc.

-------------------------------------------------------------------
About Earth Science Tech, Inc.:

WWhat is ETST?

Earth Science Tech, Inc. (ETST) is a unique Science based Biotechnology company that brings Nature’s Pharmacy to the public. We are focused on developing cutting edge Nutraceuticals, Bioceuticals, Phytoceuticals and Cosmeceuticals for the Health, Wellness and Alternative Medicine Markets that improve the quality of life for people around the world. ETST also provides natural alternatives to prescription medications through Nutritional Supplements and Dietary Supplements that help make life better for everyone and people living with common disorders and illnesses.

Nutraceuticals: A nutraceutical is a pharmaceutical-grade, medicinally or nutritionally functional food. Dr Stephen De Felice, who first used the expression nutraceutical defined it as a “food, or parts of a food, that provide medical or health benefits, including the prevention and treatment of disease”. There are sometimes different definitions of nutraceutical and functional food such as functional food is an actual, natural food that has medicinal properties, while nutraceutical is a medicinal extract taken from a natural food but sold in pill or liquid form. Example: Blueberries are a functional food. A pill or an energy drink that contains antioxidants extracted from blueberries is a nutraceutical.

Bioceuticals: Bioceuticals are natural health and wellness products, such as creams and lotions, whose active ingredients are derived from nutraceuticals

Phytoceuticals: A phytoceutical is also a form of nutraceutical. The difference is that a nutraceutical comes for a food plant, something that people regularly eat, while a phytoceutical chemical comes from a plant that is not considered part of the usual human diet.

Cosmeceuticals: Cosmeceuticals are cosmetic products that contain nutraceutical elements that deliver heath benefits along with the cosmetic use.

What are ETST Products

ETST products include CBD (Cannabidiol), a natural constituent of Hemp Oil. Cannabinoids (Cannabidiol/CBD) are natural constituents of the Hemp plant and CBD is derived from Hemp stalk and seed. Hemp oil is a well-known dietary supplement and the naturally occurring CBD and presents a continuing stream of overwhelming evidence of significant Health and Wellness benefits including; a digestive aid that regulates appetite and eases symptoms of nausea and vomiting, analgesic pain relief, relief from anxiety, anti-tumour and anti-cancer benefits, and antipsychotic. CBD (cannabidiol) promotes and supports the nutritional health of aging bodies in particular. Source: US Government Patent #6,630,507 “Cannabinoids as antioxidants and neuroprotectants.”
ETST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products. They come in various formulations and delivery systems such as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders, and whole herbs.

Isn’t Hemp illegal?

Our high grade CBD (Cannabidiol) Rich Hemp oil is classified as “food based” and is therefore perfectly permissible in all 50 US states and roughly 40 countries. With no psychoactive ingredient, CBD is a ready-for-market hemp-based nutraceutical. According to our research and on-going studies with Dr Wei R. Chen, Assistant Dean of the College of Mathematics and Science at the University of Central Oklahoma, CBD has the potential to help a range of conditions and disorders.

The United States Food and Drug Administration (FDA) currently considers non-THC hemp based cannabinoids, including CBD, to be ‘food based’ and therefore saleable. The new non-psychoactive CBD-rich hemp oil products that ETST has geared up to market and distribute are beyond reproach.

Earth Science Tech (ETST) has the highest quality and purity, full spectrum High Grade Hemp CBD (Cannabidiol) Oil, its all natural and organic made using the world’s best supercritical CO2 liquid extraction. Our test results, research and studies with the University of Central Oklahoma and DV Biologics show we’re the leading nutritional and dietary supplement brand for High Grade Hemp CBD Oil. View our website and some of our scientific studies at: (http://www.earthsciencetech.com/scientific-research/)

More Legal Stuff

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program. Cannabidiol (CBD) is a naturally occurring constituent of the industrial hemp plant and hemp oil. ETST does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US CSA). The company does sell and distribute industrial hemp-based products.

The Future for ETST

Earth Science Tech is focused on the science, research and studies of its High Grade Hemp CBD Oil as a nutraceutical and dietary supplement. In order to assure the public that ETST provides the best High Grade Hemp CBD (Cannabidiol) Oil, we continue to focus on providing the public with sound scientific research and keeping the public informed on the progression of studies being done on our High Grade Hemp CBD products. Science is what will progress the future of ETST High Grade Hemp CBD (Cannabidiol) Oil and its products. Cannabidiol (CBD) is a naturally occurring constituent of industrial hemp oil.
Join the ETST Team as a distributor or investor

Earth Science Tech currently has its Raw, Flavoured Strawberry, Flavored Peppermint High Grade Hemp CBD Oil tinctures, CBD veggie capsules, and 6 flavoured e-liquids all listed on its website for sale right now. We can provide you with single tinctures and bulk tinctures as well as bulk wholesale oil, powder, vape oil, formulations and more. We really tend to cater to our partners more than any other company out there and we take a personal approach. We are here to help you with your overall health and wellness needs.

Earth Science Tech, Inc. is a publicly traded company under ETST

Earth Science Tech (ETST) Scientific Research, Studies, Data and News on ETST High Grade Hemp CBD (Cannabidiol) Oil:

February 23, 2017 – Earth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies

April 29, 2016 – Earth Science Tech Announces Strategic Alliance with Septembers Mission Foundation to Conduct its First 30-Day Ten Participant Clinical Study with 9/11 First Responders using ETST High Grade Hemp CBD (Cannabidiol) Oil

April 11, 2016 – Earth Science Tech, Inc Announces Positive Results from First Pre-Clinical Study on New Hampshire Participate #1 of Dysfunctional Veterans with PTSD (Posttraumatic Stress Disorder) using ETST High Grade Hemp CBD (Cannabidiol)

March 28, 2016 – Earth Science Tech Announces Strategic Alliance with RRNP Healthcare and Dysfunctional Veterans of New Hampshire to conduct its First 30-Day PTSD Clinical Study with Veterans using ETST High Grade Hemp CBD (Cannabidiol) Oil

Febuary 3, 2016 – Earth Science Tech Supported Positive Scientific Research Studies and Customer Feedback on its Phytocannabinoid-CBD (Cannabidiol) Rich Hemp Oil Prompts Company to Launch Non-Profit Phytocannabinoid-CBD Research Foundation

December 9, 2015 – Earth Science Tech Announces the Conclusion of Phase 1 Trial with Former Professional Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

November 19, 2015 – Earth Science Tech Announces Positive Interim results from Trial with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

October 29, 2015 – Earth Science Tech Starts 30-day Trial Study with Former Professional Football Athletes Using ETST High Grade Hemp CBD (Cannabidiol)

October 20, 2015 – Earth Science Tech Files International PCT on its Hemp CBD (Cannabidiol) Invention and Provisional Patent “Cannabidiol Compositions Including Mixtures and Uses Thereof” Related to Treating Cancer, Modulation of the Immune System and Neuroprotection

October 16, 2015 – Earth Science Tech Announces Case Studies to Begin With Former Pro Athletes. ETST announces the start of trial studies with former professional football players using the ETST High Grade Hemp Cannabidiol (CBD)

August 18, 2015 – DV Biologics Reports: Earth Science Tech (ETST) Hemp CBD (Cannabidiol) Oil Deters the Formation of Reactive Oxygen Species (ROS) on Human Brain Cells: May serve as a Neuroprotectant

June 23, 2015 – DV Biologics, a Leading Biological Company, Reports Earth Science Tech (ETST) High Grade Hemp CBD (Cannabidiol) Oil Reduces Oxidative Stress and Lipid Peroxidation on Human Brain Cells In Vitro

May 29, 2015 – Earth Science Tech, Inc. (ETST) Announces Positive Progress on Its High Grade CBD (Cannabidiol) Rich Hemp Oil in vitro Studies on Various Human Primary Cells with DV Biologics, a Leading Biological Company

April 13, 2015 – ETST and DV Biologics Begin Testing ETST CBD (Cannabidiol) Rich Hemp Oil In Vitro on Various Human Primary Cells to See if it Serves as a Neuroprotectant Which May Help With Neurodegenerative Disorders

January 26, 2015 – Earth Science Tech Announces Positive Test Results of Its Product CBD (Cannabidiol) Rich Hemp Oil; In Collaboration with the University of Central Oklahoma, Test Results Demonstrate That CBD Rich Hemp Oil Enhances Immune Function

January 16, 2015- Earth Science Tech Secures Ground Breaking Second Provisional Patent for Its CBD (Cannabidiol) Rich Hemp Oil Because of Its Findings With the University of Central Oklahoma and the Effects of CBD on Immune Cells

November 3, 2014 – Earth Science Tech Enters Stage 2 of Research on Its Hemp Oil Enriched With CBD (Cannabidiol) on Immune Cells and Announces Multiple Patents and Clinical Trials of the CBD-Cannabinoid Compounds

October 20, 2014 – Earth Science Tech Announces and Secures New Provisional Patent for Hemp Oil Enriched With CBD (Cannabidiol) Filed With the United States Patent and Trademark Office (USPTO)
October 9, 2014 – Earth Science Tech Announces Positive Preliminary Test Results on the Effects of Its Hemp Oil Enriched With CBD-Cannabidiol on Animal Breast Cancer Cells and on Normal Cells

Septermber 22, 2014 – ETST and College of Mathematics and Science at the University of Central Oklahoma Join Forces in a Joint Effort to Study the Biological and Anti-Tumor Effects of ETST All Natural High Grade CBD (Cannabidiol) Rich Hemp Oil on Cancer Cells

.SOURCE: http://earthsciencetech.com/

Disclaimer